Products in Late Development Stage
CardioVision™
-
Is an Infarct-Avid Radiopharmaceutical imaging Agent that localizes specifically
in damaged Cardiac Cells (Myocardial infarction). Due to Cell death, the
Cell Membrane becomes permeable.
CardioVision™ specifically penetrates into the Heart cell and adheres
to the Myosin (contractile Protein). Through the Technetium Radiation
Scintigraphic imaging is available.
CardioVision has reached Phase III with 80 Patients enrolled.
Expected Revenue -
2.1 million Patients/Year in the Industrialized Countries.
- Initial projected Revenue: 175 million USD/ year.
- Projected Revenue with Stem Cell Therapy: 315-1,050
million USD/year
 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
||||
 |
 |
 |
 |
 |
|
||||
 |
|
||||||||